Abstract
Protein therapeutics, such as antibodies, enzymes and toxins, are very promising reagents for the treatment of human disease. However, many therapeutic proteins are known to elicit immune responses when administered to humans. Certain antibodies work by neutralization; others reduce drug efficacy. It is clear that helper T cells are an important factor in the development of class-switched and affinity-maturated anti-therapeutic protein antibodies. Elimination of the T cell epitope seems reasonable, but it is probably impossible to remove all T cell epitopes from protein drugs because T cell epitopes are closely related to the major histocompatibility complex (MHC) molecules, which are known to be highly polymorphic. Accordingly, a possible practical approach for reducing immunogenicity involves the removal of B cell epitopes. In this case, reducing the affinity between the antigen and the B cell receptor may reduce B cell activation, even though the T cell will still be activated. Also a B cell epitope is not restricted by MHC class II molecules. This review seeks to address the identification and the characterization of B cell epitopes, and reports on the development of strategies for reducing immune response with modified B cell epitopes.
Keywords: Toxin, antibody, B cell epitope, ELISA, conformational epitope
Current Drug Targets
Title: Reducing the Immunogenicity of Protein Therapeutics
Volume: 10 Issue: 2
Author(s): Masanori Onda
Affiliation:
Keywords: Toxin, antibody, B cell epitope, ELISA, conformational epitope
Abstract: Protein therapeutics, such as antibodies, enzymes and toxins, are very promising reagents for the treatment of human disease. However, many therapeutic proteins are known to elicit immune responses when administered to humans. Certain antibodies work by neutralization; others reduce drug efficacy. It is clear that helper T cells are an important factor in the development of class-switched and affinity-maturated anti-therapeutic protein antibodies. Elimination of the T cell epitope seems reasonable, but it is probably impossible to remove all T cell epitopes from protein drugs because T cell epitopes are closely related to the major histocompatibility complex (MHC) molecules, which are known to be highly polymorphic. Accordingly, a possible practical approach for reducing immunogenicity involves the removal of B cell epitopes. In this case, reducing the affinity between the antigen and the B cell receptor may reduce B cell activation, even though the T cell will still be activated. Also a B cell epitope is not restricted by MHC class II molecules. This review seeks to address the identification and the characterization of B cell epitopes, and reports on the development of strategies for reducing immune response with modified B cell epitopes.
Export Options
About this article
Cite this article as:
Onda Masanori, Reducing the Immunogenicity of Protein Therapeutics, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354511
DOI https://dx.doi.org/10.2174/138945009787354511 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in Efficacy of using Doxorubicin Gold Nanoparticles for Chemo-, Radio-, Photothermal, and Photodynamic Therapy
Current Drug Delivery <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry